Actuate Therapeutics Announces FDA Clearance of IND for Elraglusib

What Happened

On May 11, 2026, Actuate Therapeutics, Inc. (NASDAQ: ACTU) announced that the U.S. Food and Drug Administration cleared an Investigational New Drug (IND) application to conduct a Phase 1/2 study of elraglusib. The company issued a press release and furnished an updated corporate presentation as Exhibits 99.1 and 99.2 to its Form 8‑K (Item 7.01).

Key Details

• Date of announcement: May 11, 2026.
• Regulatory milestone: FDA cleared an IND for a Phase 1/2 clinical study of elraglusib.
• Materials filed: Press release (Exhibit 99.1) and updated corporate presentation (Exhibit 99.2) were furnished with the Form 8‑K.
• Filing category: Reported under Item 7.01 (Regulation FD Disclosure) of the Form 8‑K.

Why It Matters

IND clearance is a material clinical milestone that allows Actuate to proceed with human testing of elraglusib in a combined Phase 1/2 trial. For investors, this moves the program from preclinical/regulatory preparation toward active clinical development and gives the company a near‑term news stream to follow (trial start, design, enrollment updates). The furnished press release and presentation provide the company’s public summary and next‑step plans; investors should monitor subsequent SEC filings and clinical updates for timing and trial details.